Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Related Keywords

Jamesl Gulley ,David Sallman ,Precigen Ultraporator ,Precigen Adenoverse ,Helen Sabzevari ,Clintt Allen ,Maryl Nora Disis ,Precigen Ultra ,Steven Harasym ,Uw Center ,Development Agreement ,Linkedin ,National Cancer Institute ,H Lee Moffitt Cancer Center Research Institute ,National Institutes Of Health ,Clinical Research Division ,Drug Administration ,University Of Washington Uw Professor Medicine ,Nasdaq ,Exchange Commission ,Oncology Service ,Department Of Malignant Hematology ,Fred Hutchinson Cancer Research Center ,Precigen Inc ,Translational Medicine ,Assistant Member ,Malignant Hematology ,Moffitt Cancer Center ,Research Institute ,Branch Chief ,Medical Oncology Service ,National Institutes ,Principal Investigator ,Translational Tumor Immunology ,Orphan Drug Designation ,Dose Level ,Safety Study ,Positive Acute Myeloid Leukemia ,Higher Risk Myelodysplastic Syndromes ,Cooperative Research ,Advancing Medicine ,Sleeping Beauty ,Annual Report ,Precigen ,Nc ,